Skip to main content

Market Overview

A Preview Of Sarepta Therapeutics Q2 Earnings


Sarepta Therapeutics (NASDAQ: SRPT) announces its next round of earnings this Wednesday, August 7. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.

Earnings and Revenue

Sarepta Therapeutics EPS will likely be near a loss of $1.37 while revenue will be around $90.94 million, according to analysts.

In the same quarter last year, Sarepta Therapeutics reported an EPS loss of 43 cents on revenue of $73.53 million. Sales would be have grown 23.68% from the same quarter last year. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:


Quarter Q1 2019 Q4 2018 Q3 2018 Q2 2018
EPS Estimate -1.680 -1.04 -0.82 -0.84
EPS Actual -0.750 -0.85 -0.56 -0.43

Stock Performance

Over the last 52-week period, shares are up 18.06%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release. Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The popular rating by analysts on Sarepta Therapeutics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Sarepta Therapeutics is scheduled to hold a conference call at 4:30 p.m. ET and can be accessed here:


Related Articles (SRPT)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at